Portrait of a Killer: Genome of the 2014 EBOV Outbreak Strain  by Basler, Christopher F.
Cell Host & Microbe
PreviewsPortrait of a Killer: Genome
of the 2014 EBOV Outbreak StrainChristopher F. Basler1,*
1Icahn School of Medicine at Mount Sinai, Department of Microbiology, Box 1124, 1 Gustave L. Levy Place, New York, NY 10029, USA
*Correspondence: chris.basler@mssm.edu
http://dx.doi.org/10.1016/j.chom.2014.09.012
A recent study by Gire et al. (2014) identifies differences that make the 2014 West Africa Ebola virus unique
and details how the virus spread fromGuinea to Sierra Leone. This work highlights the power of new genomic
technologies to facilitate rapid public health and scientific responses to the crisis.The ongoing 2014 Ebola virus (EBOV)
epidemic in West Africa (see Figure 1) is
by far the largest andmost deadly appear-
ance of this virus on record. This deadly
pathogen is an enveloped virus with
a nonsegmented, negative-sense RNA
genome of nearly 19,000 bases. The
genome has seven genes that produce
eight major translation products. Replica-
tion takes place in the host cell cytoplasm
and all viral RNA synthesis reactions are
carried out by a complex of viral pro-
teins known as nucleoprotein (NP), VP35,
VP30, and the large (L) protein, the enzy-
matic subunit. Viral attachment and entry
are mediated by the membrane-bound
glycoprotein (GP) whereas assembly and
egress are directed by the viral matrix pro-
tein, VP40. A secreted glycoprotein (sGP)
that is not incorporated into viral particles
is also produced during infection.
Many of these features of replication
are similar to those of more benign vi-
ruses. Reflecting in part the limited
availability of high-containment facilities
suitable for work with these extreme path-
ogens, exactly what makes EBOV so
deadly is only partly understood. The virus
is thought to initially target macrophages
and dendritic cells. Because it encodes
very effective antagonists of the innate
immune system, EBOV fails to trigger
effective innate antiviral defenses and is
able to replicate robustly. Because of
these innate immune-suppressive func-
tions, the virus also fails to trigger den-
dritic cell maturation, which impairs
adaptive immune responses as well. As
infection proceeds, robust replication
ultimately results in systemic spread,
apoptosis of lymphocytes, and release
of inflammatory mediators that likely
trigger many of the symptoms associated
with EBOV disease.An important recent study published in
Science by Gire et al. (2014) provides
the most detailed scientific characteriza-
tion of the deadly virus causing the
ongoing 2014 EBOV epidemic and also
provides insights into how it has spread
through the human population. The study
used massively parallel sequencing to
determine the sequence of EBOV ge-
nomes from 78 different patients in
Liberia. The data, combined with com-
plete viral genome sequences from three
earlier Guinea isolates, were used to
address fundamental questions regarding
the introduction and spread of EBOV from
Guinea to Sierra Leone. Specifically, the
authors provide support for the introduc-
tion of a single virus into the human
population, a conclusion that is consistent
with a study of earlier Guinea isolates
(Baize et al., 2014). Their comparisons of
the 2014 viral sequences to those of
past outbreak strains suggest that these
strains diverged from a common ancestor
roughly a decade ago. By combining
epidemiologic information with viral ge-
netic data, the authors were able to track
the first documented case in Sierra Leone
as coming from Guinea. Specifically, it
was demonstrated that attendees at a
funeral in Guinea became infected and
introduced two genetic variants into
Sierra Leone. The authors were able to
then track the spread of the virus to
different sites in Sierra Leone and to iden-
tify the emergence of a new genetic line-
age (Gire et al., 2014). These data provide
in unprecedented detail a description of
how EBOV spreads among human popu-
lations and how it changes genetically
over time as it transmits from person to
person.
The EBOVs sequenced thus far are
phylogenetically distinct from the virusesCell Host & Microbe 1that caused earlier outbreaks, differing
by approximately 3% at the nucleotide
level. They also possess unique genetic
changes that distinguish the current strain
from others, just as prior outbreak strains
have exhibited their own unique genetic
changes. Currently, we do not know
whether such genetic differences have
any impact on viral replication, transmissi-
bility, or pathogenesis. Clearly, viruses
that cause outbreaks are pathogenic in,
and transmissible between, people. To
what extent, if at all, such genetic differ-
ences determine how outbreaks play out
remains largely unaddressed. Experi-
mental approaches to address such
questions would include systematic
comparisons of virus replication in exper-
imental settings and functional compari-
sons of varying viral gene products. The
analyses performed by Gire and col-
leagues provide a groundwork upon
which such studies can be built (Gire
et al., 2014).
Their analysis also demonstrates an
increased rate of nonsynonymous amino
acid changes among 2014 isolates versus
viruses from earlier outbreaks. Among
these are substitutions in multiple viral
proteins including NP, GP, and L. Genetic
change is obviously of concern given that
the RT-PCR-based diagnostics being
used are sequence based. As pointed
out by the authors, the genetic changes
occurring as the virus spreads also raise
the specter of viral adaptation to humans.
Adaptation would not necessarily require
dramatically altered modes of transmis-
sion, but might simply reflect increased
efficiency of transmission through contact
with bodily fluids. Any such change would
further raise the barrier to stopping the
epidemic. In many respects the virus is
already well adapted to people as it can6, October 8, 2014 ª2014 Elsevier Inc. 419
Figure 1. Map Depicting the 2014 Ebola Virus Outbreak in West Africa as of September 20, 2014
Image credit: ‘‘2014 Ebola virus epidemic in West Africa’’ by Mikael Ha¨ggstro¨m, licensed under Creative Commons CC0 1.0 Universal Public Domain Dedication
(http://creativecommons.org/publicdomain/zero/1.0/deed.en).
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with apparent efficiency from person to
person. In addition, while comparisons
of EBOVs from different outbreaks
demonstrate genetic drift over time, char-
acterization of viruses isolated from the
same outbreak, including those isolated
from short chains of human-to-human
transmission, have not revealed obvious
signs of evolution or adaptation to people
(Carroll et al., 2013). Nonetheless, the
unprecedented duration of the present
outbreak provides opportunities for the
virus to change. Given the possibility of
adaptation, ongoing sequencing efforts
of new isolates will be important.
What adaptive changes might look like
at the sequence level is difficult to predict.
EBOVs have been adapted to mice and
guinea pigs by serial passage (Bray
et al., 1998; Volchkov et al., 2000). This
experimental adaptation has been neces-
sary because while mice and guinea pigs
are desirable as small animal models of
infection, EBOV does not cause disease
in immune-competent rodents. Serial
passage selects for genetic changes in
the virus that allow it to become more
lethal. The procedure involves intraperito-
neal inoculation of animals, sacrifice of
the animals at a time point when the virus
has had a chance to amplify itself, homog-
enization of the liver, a major site of repli-420 Cell Host & Microbe 16, October 8, 2014cation, and inoculation of the homogenate
into new animals. The process selects for
robust replication in the organ sampled
and this results in a virus that kills these
otherwise resistant species. Of course,
this method eliminates the need for the
virus to transmit. Nevertheless, character-
izations of the adapted viruses have
identified amino acid changes in specific
proteins as the minimal changes needed
to confer lethality in the respective hosts,
and the mouse-adapted virus has an
increased resistance to the antiviral
effects of type I interferons in vitro
(Ebihara et al., 2006; Mateo et al., 2011).
However, EBOV already possesses
several effective mechanisms to coun-
teract innate immune responses in human
cells (Basler and Amarasinghe, 2009).
Therefore, it is unclear whether these
mechanisms are under selective pressure
in infected humans.
Whether any specific genetic change
will alter viral functions will be difficult
to discern based on sequence analysis
alone. Several functionally significant
sequencemotifs are known from previous
work. For example, domains in the viral
glycoprotein required for entry, regions
of the VP35 protein required to suppress
interferon responses, and late domains
in the viral VP40 matrix protein needed
for viral egress have been identified. How-ª2014 Elsevier Inc.ever, many of the interfaces that mediate
interactions between viral proteins are
not defined, there is minimal information
to link genetic changes with altered virus
replication, and how specific interactions
among viral and host factors modulate
virus biology in vivo remains poorly under-
stood. It is also notable that, in contrast to
many other negative-sense RNA viruses,
filoviruses devote a substantial amount
of genetic material to noncoding regions.
For EBOV, more than 20%of the genome
is non-protein-coding. Among these non-
coding regions are sequences that func-
tion as cis-acting regulatory elements
directing viral transcription and replica-
tion. In addition, a large amount of the viral
genome encodes 50 and 30 untranslated
regions present in viral mRNAs. Within
some of these sequences are predicted
secondary structures and upstream
open reading frames that are known to
modulate replication or viral mRNA trans-
lation (Mu¨hlberger, 2007; Shabman et al.,
2013). However, the function and signifi-
cance of the vast majority of these
sequences remains a black box.
Given the absence of functional do-
mains known to modulate virus-host in-
teractions, it will be necessary to couple
genetic studies with other types of ana-
lyses to understand how variation is
impacting virus behavior. This can be
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methods that look for altered signs
of transmission or virulence in the
human population. However, additional
genetic and molecular experimental
approaches will be needed to be sure
that what is happening in the human pop-
ulation is related to changes in viral ge-
netics. Ongoing monitoring of specimens
collected for diagnostic purposes should
be performed. Virological studies com-
paring the replication of EBOV isolates
with different genetic sequences can
also be performed, but this requires
biosafety level 4 containment labs. Addi-
tionally, assays that recapitulate themajor
steps in the virus replication cycle are
available and can be employed.
Collecting specimens from EBOV pa-
tients comes with risk and, tragically,
four coauthors on the Science paper con-
tracted and succumbed to EBOVdisease.
Gire and colleagues can be commended
for rapidly determining these viral se-
quences and for publically releasing the
data as they became available (Gire
et al., 2014). This openness facilitates
public health efforts to contain theepidemic and scientific efforts to under-
stand it. The sequences that have been
reported thus far were collected up until
mid-June. Therefore, nearly three months
of continuing transmission have elapsed
with no significant new sequence data
made available through public databases.
Hopefully, the genetic material collected
for diagnostic purposes will also be put
to good use to better understand and
respond to the ongoing and tragic
epidemic.
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A small number of tissue-resident memory T cells (Trm) provide potent protection against infections. Three
recent studies by Ariotti et al. (2014), Schenkel et al. (2014a), and Iijima and Iwasaki (2014) report that Trm
rapidly produce cytokines after infection and initiate a tissue-wide anti-viral state by instructing innate
immune cells.Cells of the innate immune system such
as macrophages, neutrophils, and den-
dritic cells rapidly respond to infection
by phagocytosing and destroying mi-
crobes. Additionally, these cells are
capable of initiating a tissue-wide inflam-matory/anti-microbial state when they
sense danger through their pattern re-
cognition receptors (PRRs). PRRs are
not specific for a particular pathogen
antigen but recognize common microbial
traits (e.g., LPS from gram negative bac-teria, unmethylated CpG DNA from bac-
teria and DNA viruses). T cells, on the
other hand, can provide a very specific
response through their clonal T cell recep-
tors and are pivotal in the elimination
intracellular pathogens. However, naı¨ve6, October 8, 2014 ª2014 Elsevier Inc. 421
